Condition
Metastatic Castration-resistant Prostate Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 158 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04
RECRUITINGA Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerNCT07365995 · 2026-04-22
RECRUITINGStudy of JANX014 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT07545811 · 2026-04-15
RECRUITINGACTinium in Castrate-RESistant Prostate Cancer After LUTEtiumNCT07414940 · 2026-04-13
RECRUITINGSupraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseNCT07142551 · 2026-03-09
RECRUITINGPhase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPCNCT07476001 · 2026-03-03
RECRUITINGDual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate CancerNCT07641049 · 2026-03-02
RECRUITINGStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07288359 · 2025-12-29
RECRUITINGA Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07244341 · 2025-12-03
RECRUITINGA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28
RECRUITINGA Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)NCT07103018 · 2025-11-21
RECRUITINGA Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerNCT07189403 · 2025-11-04
RECRUITINGThe COSMYC Trial (COmbined Suppression of MYC)NCT06922318 · 2025-08-19
RECRUITINGCabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerNCT06738303 · 2025-07-14
RECRUITINGA Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerNCT06533644 · 2025-05-29
RECRUITINGPost Marketing Study on Pluvicto in KoreaNCT06514521 · 2025-04-18
RECRUITINGStudy of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate CancerNCT06866938 · 2025-04-11
RECRUITINGPlatinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response GenesNCT06439225 · 2024-12-30
RECRUITINGXL092 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06568562 · 2024-12-09
RECRUITINGRadiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPCNCT06971211 · 2024-11-27
RECRUITINGIntestinal Akkermansia Muciniphila in Prostate CancerNCT06242509 · 2024-11-20
RECRUITINGStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerNCT06228053 · 2024-11-18
RECRUITINGAutologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCNCT06193486 · 2024-10-26
RECRUITINGDarolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06401980 · 2024-10-22
RECRUITINGStudy With [225Ac]Ac-FL-020 in mCRPC ParticipantsNCT06492122 · 2024-08-30
RECRUITINGThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)NCT06520345 · 2024-07-26
RECRUITINGEfficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line TreatmentNCT06529549 · 2024-07-24
RECRUITINGEbastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate CancerNCT06480110 · 2024-06-20
RECRUITINGPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide TetraxetanNCT06099093 · 2024-04-01
RECRUITINGPROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29
RECRUITINGA Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC PatientsNCT06155084 · 2023-12-26
RECRUITINGSipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCNCT06100705 · 2023-12-20
RECRUITINGPembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerNCT05766371 · 2023-12-15
RECRUITINGDocetaxel or Cabazitaxel With or Without Darolutamide in mCRPCNCT05762536 · 2023-11-29
RECRUITINGA Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerNCT06067841 · 2023-10-18
RECRUITINGDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerNCT05613894 · 2023-07-14
RECRUITING64Cu-GRIP B in Patients With Advanced MalignanciesNCT05888532 · 2023-05-25
RECRUITINGFOG-001 in Locally Advanced or Metastatic Solid TumorsNCT05919264 · 2023-05-23
RECRUITINGPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).NCT05720130 · 2023-03-15
RECRUITING177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate CancerNCT05603559 · 2023-01-01
RECRUITINGEValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&TNCT05521412 · 2022-09-29
RECRUITINGStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)NCT05519449 · 2022-09-15
RECRUITINGStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · 2022-09-06
RECRUITINGAnti-tumour Activity of (177Lu) rhPSMA-10.1 InjectionNCT05413850 · 2022-07-20
RECRUITINGAbemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerNCT05113537 · 2022-07-08
RECRUITINGA Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerNCT05125016 · 2021-11-30
RECRUITINGA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNCT04104776 · 2019-09-18
RECRUITINGPhase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate CancerNCT07608718 · 2026-10-01
NOT_YET_RECRUITINGChemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical TherapyNCT07609225 · 2026-10-01
NOT_YET_RECRUITINGA Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard TherapyNCT07423117 · 2026-02-06
NOT_YET_RECRUITINGClinical Trial to Evaluate the Tolerance of TQB3201 TabletsNCT07172126 · 2025-09-01
NOT_YET_RECRUITINGClinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPCNCT06895811 · 2025-03-27
ACTIVE_NOT_RECRUITINGA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · 2025-03-13
ACTIVE_NOT_RECRUITINGFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06909825 · 2025-02-26
ACTIVE_NOT_RECRUITINGPhase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09
ACTIVE_NOT_RECRUITINGA Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerNCT07553988 · 2024-10-24
ACTIVE_NOT_RECRUITING177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate CancerNCT06329830 · 2024-10-01
WITHDRAWNLuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerNCT06303713 · 2024-05-22
ACTIVE_NOT_RECRUITINGA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPCNCT06383052 · 2024-04-26
ACTIVE_NOT_RECRUITING[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate CancerNCT06229366 · 2024-04-03
ACTIVE_NOT_RECRUITINGCommon interventions
enzalutamideDRUG13OlaparibDRUG10AbirateroneDRUG8abiraterone acetateDRUG8DocetaxelDRUG8PrednisoneDRUG7DarolutamideDRUG6CabazitaxelDRUG5177Lu-PSMA-617DRUG4Radium-223DRUG4BevacizumabDRUG3CarboplatinDRUG3CyclophosphamideDRUG3FludarabineDRUG3NivolumabDRUG3Testosterone cypionateDRUG3AbemaciclibDRUG2Abiraterone acetate tabletsDRUG2AcapatamabDRUG2AtezolizumabDRUG2AvelumabDRUG2FPI-2265DRUG2FulvestrantDRUG2HP518 - Dose EscalationDRUG2Luteinizing hormone-releasing hormone (LHRH) analogueDRUG2
Leading sponsors
AstraZeneca
9
Amgen
5
Peking Union Medical College Hospital
5
Rahul Aggarwal
5
University of Utah
5
Dana-Farber Cancer Institute
4
Peter MacCallum Cancer Centre, Australia
4
Bayer
3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3
Exelixis
3
Novartis Pharmaceuticals
3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3
Sun Yat-sen University
3
BAMF Health
2
Daiichi Sankyo
2
Trial status mix
RECRUITING47
COMPLETED31
ACTIVE_NOT_RECRUITING30
TERMINATED23
UNKNOWN19
NOT_YET_RECRUITING4
WITHDRAWN2
APPROVED_FOR_MARKETING1
ENROLLING_BY_INVITATION1
Phase mix
PHASE177
PHASE275
PHASE316
EARLY_PHASE17
NA3
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.